The surrogate endpoint offers an alternative to traditional fracture endpoints used in clinical trials of osteoporosis drugs ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

Boston-based Beth Israel Deaconess Medical Center played a role in a new FDA decision that allows bone mineral density, measured through noninvasive imaging, to serve as a qualified endpoint in ...

For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...

LOS ANGELES - With the launch of the first prescription osteoporosis medication 15 years ago, millions of Americans with the bone-thinning disease began taking the drugs and never looked back. But now ...

On Monday, the Food and Drug Administration issued a new draft guidance that requires drug manufacturers to conduct long-term nonclinical bone quality studies for osteoporosis treatments. The agency ...

Please provide your email address to receive an email when new articles are posted on . It will be “many years” before any new pharmacologic osteoporosis therapies are approved, as there are currently ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Understanding when to switch from one class of drugs to another is critical to maintaining bone ...

A long-term study of the most widely used osteoporosis drug has found that many women can discontinue the drug after five years without increasing their fracture risk for as long as five more years.

A drug widely used to treat osteoporosis might reduce the risk of Type 2 diabetes, a new study suggests. Taking the drug alendronate, or Fosamax, for at least eight years could potentially reduce a ...

An experimental drug has successfully reduced hip and spine fractures in the two largest patient populations at risk for osteoporosis — postmenopausal women and men being treated for prostate cancer — ...